Sensitivity profiling reveals consistent drug responses across preclinical neuroblastoma models
Marlinde C. Schoonbeek, Marloes van Luik, Heike Peterziel, Dennis Gürgen, Vicky Amo-Addae, Lindy Vernooij, Eleonora J. Looze, Sabina Valova, Sina Kreth, Jan Köster, Angelika Eggert, Julia B. Schüler, Aniello Federico, Apurva Gopisetty, Benjamin Schwalm, , Sander R. van Hooff
This study compares ex vivo short-term, organoid, and PDX drug screening methods in neuroblastoma, finding ex vivo screens are faster and more consistent with in vivo results.
bioRxiv · Feb 25, 2026 · PreprintCell Biology